Headlines Covid-19 Specialties Trending Feeds Videos

Original Article from The New England Journal of Medicine — Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against

  • Here’s the ⁦@NEJM⁩ article for the phase 3 J&J vaccine trial. Very good efficacy in a trial with a lot of variants. Efficacy gets better over time and increases to 92% against severe-critical disease after 42 days. 1 case of CSVT in each group. https://t.co/3eIDcr0Fe6 - view on twitter